Patents Examined by Bruce R. Campell
-
Patent number: RE49050Abstract: A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.Type: GrantFiled: December 13, 2019Date of Patent: April 26, 2022Assignee: Tasly Pharmaceutical Group Co., Ltd.Inventors: Xijun Yan, Naifeng Wu, Kaijing Yan, Zhengliang Ye, Shunnan Zhang, Lihong Zhou, Wensheng Zhang, Hai'ou Dong, Yongfeng Zheng, Lijun Fan
-
Patent number: RE49076Abstract: Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.Type: GrantFiled: July 23, 2019Date of Patent: May 17, 2022Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: David J. Friedman, Martin R. Pollak
-
Patent number: RE49121Abstract: A genetically modified mouse is provided that comprises a conditional Acvr1 allele that comprises a mutated exon that, upon induction, converts to a mutant exon phenotype, wherein the mutant exon phenotype includes ectopic bone formation. Mice comprising a mutant Acvr1 exon 5 in antisense orientation, flanked by site-specific recombinase recognition sites, are provided, wherein the mice further comprise a site-specific recombinase that recognizes the site-specific recombinase recognitions sites, wherein the recombinase is induced upon exposure of the mouse to tamoxifen. Upon exposure to tamoxifen, the recombinase is expressed and acts on the RRS-flanked mutant exon 5 and places the mutant exon 5 in sense orientation and deletes the wild-type exon.Type: GrantFiled: November 13, 2018Date of Patent: July 5, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Aris N. Economides, Sarah Jane Hatsell
-
Patent number: RE49129Abstract: The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.Type: GrantFiled: June 27, 2019Date of Patent: July 12, 2022Assignee: GRIFOLS WORLDWIDE OPERATIONS LIMITEDInventors: David A. Ross, Ralph Christian Crumrine
-
Patent number: RE49192Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.Type: GrantFiled: May 30, 2019Date of Patent: August 30, 2022Assignee: INTERNATIONAL—DRUG—DEVELOPMENT BIOTECHInventors: Claudine Vermot-Desroches, Boris Sebastien Vuillermoz
-
Patent number: RE49207Abstract: Provided herein, among other things, are a variety of methods for transposase-mediated tagging and amplification of short DNA fragments, e.g., between about 150 bp and 1.5 Kb in length. In some aspects, the method includes tagging the DNA fragments with a first primer sequence using barcoded transposases followed by a primer extension reaction to introduce a second primer sequence, e.g., using random or gene-specific primers. Kits for performing this method are also provided.Type: GrantFiled: November 8, 2019Date of Patent: September 13, 2022Assignee: Agilent Technologies, Inc.Inventors: Bahram Arezi, Michael Borns, Holly Hogrefe, Connie Hansen
-
Patent number: RE49229Abstract: This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-?.Type: GrantFiled: February 28, 2020Date of Patent: October 4, 2022Assignee: NITTO DENKO CORPORATIONInventors: Kenjirou Minomi, Jihua Liu, Li Wang, Bharat Majeti, Roger Adami, Wenbin Ying
-
Patent number: RE49238Abstract: Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).Type: GrantFiled: August 19, 2020Date of Patent: October 11, 2022Assignee: Retrotope, Inc.Inventor: Mikhail S. Shchepinov
-
Patent number: RE49281Abstract: The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.Type: GrantFiled: December 13, 2019Date of Patent: November 8, 2022Assignee: Whitehead Institute for Biomedical ResearchInventors: Brett Chevalier, Alexander Marson, Richard A. Young, Ruth Foreman, Rudolf Jaenisch
-
Patent number: RE49293Abstract: Gas permeable devices and methods are disclosed for cell culture, including cell culture devices and methods that contain medium at heights, and certain gas permeable surface area to medium volume ratios. These devices and methods allow improvements in cell culture efficiency and scale up efficiency.Type: GrantFiled: June 12, 2018Date of Patent: November 15, 2022Assignee: Wilson Wolf ManufacturingInventors: John R. Wilson, Douglas A. Page, Daniel Welch, Alison Robeck
-
Patent number: RE49294Abstract: A vector production system is provided. The system comprises recombinant cells designed to encode at least a first recombinase under the control of an inducible promoter and the cells include an expression vector encoding a nucleic acid of interest within the regulatory elements of the expression vector which are flanked on either side by a target sequence for at least the first recombinase. The vector production system provides an efficient one-step process for producing linear or circular covalently closed vectors that incorporate a nucleic acid sequence of interest.Type: GrantFiled: March 5, 2020Date of Patent: November 15, 2022Assignee: Mediphage Bioceuticals, Inc.Inventors: Roderick Slavcev, Nafiseh Nafissi
-
Patent number: RE49304Abstract: Provided herein are compositions and methods for identifying or quantitating one or more analytes in sample. The composition can comprise an affinity molecule reversibly conjugated to a label moiety via a double-stranded nucleic acid linker or via an adaptor molecule. The affinity molecule and the label moiety can be linked to different strands of the double-stranded nucleic acid linker. Compositions can be used in any biological assays for detection, identification and/or quantification of target molecules or analytes, including multiplex staining for molecular profiling of individual cells or cellular populations. For example, the compositions can be adapted for use in immunofluorescence, fluorescence in situ hybridization, immunohistochemistry, western blot, and the like.Type: GrantFiled: April 3, 2020Date of Patent: November 22, 2022Assignee: University of WashingtonInventors: Xiaohu Gao, Pavel Zrazhevskiy
-
Patent number: RE49311Abstract: Compositions are provided that include a new Bacillus thuringiensis strain designated RTI545 for use in benefiting plant growth and controlling plant pests. In particular, the RTI545 strain is useful for controlling plant nematode, insect and fungal pests. The compositions include plant seeds coated with the RTI545 strain. The compositions can be applied alone or in combination with other microbial, biological, or chemical insecticides, fungicides, nematicides, bacteriocides, herbicides, plant extracts, plant growth regulators, or fertilizers. In one example, enhanced growth and insect control are provided by delivering at the time of planting a combination of a chemical insecticide such as bifenthrin and a liquid fertilizer to plants or seeds treated with RTI545.Type: GrantFiled: January 22, 2020Date of Patent: November 29, 2022Assignee: FMC CorporationInventors: Daniel Van Der Lelie, Safiyh Taghavi, Vincent J. Spadafora, Nathan Caldwell, Anders Obel, Robert B. Albright, Guozhi Wang, Jaeheon Lee, Roderick G. McLeod, Kevin Brost, John E. Kibbee
-
Patent number: RE49422Abstract: In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.Type: GrantFiled: August 30, 2020Date of Patent: February 21, 2023Assignee: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati, Nicola Caronzolo
-
Patent number: RE49423Abstract: The present invention relates to the production and use of covalently closed circular (ccc) recombinant plasmids, and more particularly to vector modifications that improve expression of said DNA molecules in the target organism.Type: GrantFiled: December 4, 2020Date of Patent: February 21, 2023Assignee: Nature Technology CorporationInventor: James A. Williams
-
Patent number: RE49443Abstract: In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.Type: GrantFiled: August 30, 2020Date of Patent: March 7, 2023Assignee: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati, Nicola Caronzolo
-
Patent number: RE49444Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: December 24, 2020Date of Patent: March 7, 2023Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle, Zhengxin Dong
-
Patent number: RE49477Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.Type: GrantFiled: October 2, 2019Date of Patent: March 28, 2023Assignee: Thomas Jefferson UniversityInventors: Andrzej Fertala, Andrzej Steplewski
-
Patent number: RE49529Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.Type: GrantFiled: December 3, 2020Date of Patent: May 16, 2023Assignee: Inozyme Pharma, Inc.Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill
-
Patent number: RE49555Abstract: In a first aspect, the present invention relates to a process for producing a stable, injectable solution with low content of noradrenaline, which includes dissolving noradrenaline and optionally an excipient in deoxygenated or degassed water, filtrating the resulting noradrenaline solution in a nitrogen current, distributing the solution in a nitrogen current, and sterilization, preferably hot. The invention further provides a stable, injectable solution with low content of noradrenaline, substantially free of anti-oxidizing and preservative agents, as well as uses thereof in the medical and pharmaceutical fields.Type: GrantFiled: August 30, 2020Date of Patent: June 20, 2023Assignee: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati, Nicola Caronzolo